MAY 2022

GREETINGS!

We are hoping to see you this month in person! First, our Chair, Sundari Mase, will be facilitating a session titled “Setbacks and Silver Linings: COVID-19 impact on TB,” May 16, during the ATS 2022 Conference, International Participants Center Program. Second, our Chair-Elect, Cynthia A. Tschampl, will be leading a lunch training session at the National TB Conference on May 24th, and we will have a booth that several from the Coordinating Board will help run. RSVP here for the training and please stop by to say “Hi” (and maybe win a door prize!) if you attend the conference. You know we can’t #EndTB without you!

DC UPDATE

Contact your Senators and Representatives!

There are lots of #TBElimination reasons to contact your Members of Congress. Please ask your Senators to support the following funding levels in fiscal year 2023 appropriations bills:

$225 million for CDC’s TB program in FY2023 through Labor-HHS Appropriations.

Every US state reports cases of TB annually, many states report deaths from TB, and there are up to 13 million people in the U.S. with latent TB infection. In the absence of a targeted prevention program, these individuals represent the reservoir of future active TB cases.

$21 million in dedicated funding for CDC’s Division of Global HIV and TB.

CDC’s mandate is to protect Americans from public health threats at home and abroad. Yet its work on global TB is underfunded. Increased funding would allow the agency to address the nexus between global TB epidemics and the incidence of TB in the U.S. by strengthening TB elimination programs especially in countries contributing to the TB burden in the U.S. such as Mexico, Vietnam, and the Philippines.

Include TB in the CDMRP Peer Reviewed Medical Research Program in Fiscal Year 2023.

TB was first included on PRMRP the eligible disease list in FY 2016 but has been excluded ever since. During the time it was included, over $23 million was awarded to TB research and development institutions around the US. This program is a critical part of the US government’s TB research infrastructure and we urge you to ensure its inclusion on the list of eligible diseases again in FY 2023.

$1 billion for bilateral TB efforts in FY2023 State and Foreign Ops Appropriations.

USAID’s TB program provides technical assistance to 23 of the world’s most highly burdened countries, supports research and development and the Global Drug Facility. Additional funding is needed for USAID’s TB program to help countries
adapt and restore TB programs, support the development of new TB diagnostic, treatment, and prevention tools, and prevent a dangerous reversal of progress against TB.

Finally...

**A chance to Co-sponsor the Comprehensive TB Elimination Act of 2021**

The Comprehensive TB Elimination Act of 2021 has now been reintroduced in both the Senate and in the House of Representatives. This reauthorizing bill is meant to fund domestic TB programs and focus TB elimination and research resources on priority populations in the US. Please read more about the legislature here and join the effort to gain cosponsors for the bill by contacting your senators and representatives. A sample script and instructions can be found on our website.

**ANNOUNCEMENTS**

**NIH funds new tuberculosis research advancement centers**

**HIGHLIGHTED TB REPORTS/UPDATES**

- Report: WHO technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments
- Iavi and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies
- Stop TB Partnership - World TB Day 2022 Campaign Update

**Provisional TB Surveillance Data for 2021**


The COVID-19 pandemic has had a substantial effect on TB disease trends in the United States. Before COVID-19, TB disease diagnoses typically declined between 1% and 2% each year. However, during the COVID-19 pandemic, reported TB disease diagnoses fell 20% in 2020 and remained 13% lower in 2021 than pre-pandemic levels. While these changes represent true reduction in TB disease, concerns remain about missed or delayed TB disease diagnoses. CDC has information and resources to help providers prevent, diagnose, and treat TB.

*Read more reports and updates on our website page ‘From TB Wire’*

**TB IN THE NEWS**

- The potential perils of a drug protection framework in tuberculosis
- Implications of bedaquiline-resistant tuberculosis
- Tuberculosis patients in Ukraine at risk, some refugee groups to be tested
- Less than half of people with latent TB in the US initiate therapy
- Somebody at San Ysidro High Had Tuberculosis and Exposed Students and Staff: Health Officials
- TB survivors should have been central to redesigning care policies, not reduced to an afterthought
- COVID-19 effect on TB presentation and outcome
- It would take 500 years for TB vaccine development to get as much money as COVID-19

*Read lots more TB news on our website page ‘From TB Wire’*

**TB RESOURCES**

- Community-led Monitoring for Access to Tuberculosis Screening and Diagnostic Testing
TB Education Materials Now Available in Ukrainian

CDC’s Questions and Answers about Tuberculosis booklet and Tuberculosis: General Information fact sheet are now available in Ukrainian.

NEW Think, Test, Treat TB Campaign Resources

CDC’s Campaign Resource Overview is a guide to Think, Test, Treat TB materials available for patients and healthcare providers to raise awareness of latent TB infection. Check out all the campaign materials and resources available on www.cdc.gov/thinktesttreattb.

Find more TB resources on our website page ‘TB Resources’!

JOURNAL ARTICLES

- atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure
Early alveolar macrophage response and IL-1R-dependent T cell priming determine transmissibility of Mycobacterium tuberculosis strains

When it comes to stopping tuberculosis, what is actually “missing”?


Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts

Discover many more peer-reviewed articles on our website page ‘Peer-Reviewed Publications’!

COURSES/WORKSHOPS

Summer 2022 – McGill Summer Institutes in Global Health TB course

The Union Courses Newsletter

The Union: Programmatic and Clinical Management of Drug-Resistant Tuberculosis

EVENTS, MEETINGS, & CONFERENCES

May 4th, 2022 – From Evidence to Action: Community-led Monitoring for Access to TB Screening and Diagnostic Testing

May 5th, 2022 – WHO webinar: End TB E-learning platform

May 13th-18th, 2022 – ATS 2022

May 23rd-26th, 2022 – NTCA 2022 National TB Conference - TB Elimination: Back in Focus

November 8th-11th – World Conference on Lung Health 2022 – Combating Pandemics: Today & Tomorrow

Stop TB USA: Where we unite to #EndTB!

Stop TB USA
stoptbusa.org
leadership@stoptbusa.org
1150 18th St NW Suite 300, Washington DC 20036-3803, US